Soluble Semaphorin 4D/CD100 Is Increased in the Saliva of Sjögren’s Syndrome

Shin Eui Kang¹, Jeong Seok Lee², Ji Soo Park¹, Ji Hye Lee², Jeong Yeon Kim¹, Hyun Jung Yoo², Yun Jong Lee³, Eun Young Lee⁴, Eun Bong Lee² and Yeong Wook Song^1,5, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: SICCA, Sjogren's syndrome and salivary gland

Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Sjögren’s syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration in exocrine organs with dry mouth and dry eyes. Semaphorin 4D (SEMA4D) / CD100 was reported to be highly expresed in salivary gland. Its abnormal expression in immune cells has been reported to be associated with autoimmunity. Membrane-bound SEMA4D could be proteolytically cleaved to soluble SEMA4D (sSEMA4D). This study was aimed to evaluate the sSEMA4D from saliva in patients with SS.

Methods:

Total 47 SS patients, 34 sicca patients with non-SS and 28 healthy controls were examined. Saliva samples were collected on ice, centrifuged, and stored at -80°C with treatment of protease inhibitors. Salivary sSEMA4D was measured by ELISA kit. Area under the ROC curve (AUC) was analyzed to assess the sSEMA4D as a diagnostic marker of SS. Levels of sSEMA4D were presented as median (interquartile ranges [IQR]).

Results:

The levels of salivary sSEMA4D were increased in patients with SS compared to healthy controls (median [IQR], 290.8 [188.3-478.0] vs. 170.0 [95.6-265.6] ng/mL, p = 0.002). The sSEMA4D from sicca patients with non-SS (220.0 [135.8-330.5] ng/mL, p = 0.123) was similar to that of HC. Salivary sSEMA4D was not correlated with ESR (Spearman’s rho = 0.196, p = 0.274) or CRP (Spearman’s rho = -0.225, p = 0.280) in SS. In analysis of ROC curve, the levels of salivary sSEMA4D showed acceptable accuracy to distinguish the SS patients from healthy controls (AUC = 0.710, 95% confidence interval : 0.594-0.827, p = 0.002), and optimal cut off value for diagnosis of SS is 235.5 ng/mL, with a sensitivity of 63.8% and a specificity of 71.4% (chi-square test p = 0.003).

Conclusion:

Salivary sSEMA4D was increased in patients with SS and may be useful as a potential marker to diagnose SS by non-invasive method.

Disclosure: S. E. Kang, None; J. S. Lee, None; J. S. Park, None; J. H. Lee, None; J. Y. Kim, None; H. J. Yoo, None; Y. J. Lee, None; E. Y. Lee, None; E. B. Lee, None; Y. W. Song, None.

To cite this abstract in AMA style:

Kang SE, Lee JS, Park JS, Lee JH, Kim JY, Yoo HJ, Lee YJ, Lee EY, Lee EB, Song YW. Soluble Semaphorin 4D/CD100 Is Increased in the Saliva of Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/soluble-semaphorin-4d-cd100-is-increased-in-the-saliva-of-sjogrens-syndrome/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/soluble-semaphorin-4d-cd100-is-increased-in-the-saliva-of-sjogrens-syndrome/